Clinical Study Results
What serious adverse reactions happened during this study?
There was 1 serious adverse reaction that happened during this study. This was
the low production of hormones by the adrenal glands. This happened in 2.4% of
participants during the durvalumab treatment period of the study. This was 1 out of
42 participants.
None of the participants died due to serious adverse reactions.
What adverse reactions happened during this study?
The most common adverse reactions were fatigue and itching.
The table below shows the most common adverse reactions that happened in 4 or
more participants during the study. There were other adverse reactions, but these
happened in fewer participants.
Most common adverse reactions during the study
Durvalumab and
MEDI9090
Adverse reaction (out of 42 participants)
Fatigue 26.2% (11)
Itching 26.2% (11)
Diarrhea 14.3% (6)
Nausea 14.3% (6)
Chills 11.9% (5)
How has this study helped patients and researchers?
This study helped researchers learn more about immune reactions and the safety
of durvalumab and MEDI9090 in participants with advanced solid tumors.
Researchers look at the results of many studies to decide which treatments work
best and are safest. This summary shows only the main results from this one study.
Other studies may provide new information or different results.
Further clinical studies with these study drugs are not planned.
7